Myeloid TGF-β responsiveness promotes metastases.
Tumor-induced immune suppression is a major impediment to many potentially effective cancer therapies. TGF-β has previously been described as having both tumor-promoting and tumor-suppressive characteristics. In this issue of Cancer Discovery, Pang and colleagues show that myeloid-specific TGF-β signaling is a critical mediator in tumor metastasis. These findings point to a more specific means to reduce cancer immunosuppression, prevent metastasis, and minimize treatment-related adverse events.
Immunology in Cancer and Infection Laboratory, Queensland Institute of Medical Research, University of Queensland, Herston, Queensland, Australia.
Fernando
F
Souza-Fonseca-Guimaraes
Mark J
MJ
Smyth
D000818:Animals; D006801:Humans; D022423:Myeloid Cells / Q000378:metabolism*; D009362:Neoplasm Metastasis; D017346:Protein Serine-Threonine Kinases / Q000235:genetics*; D000077294:Receptor, Transforming Growth Factor-beta Type II; D018125:Receptors, Transforming Growth Factor beta / Q000235:genetics*; D015398:Signal Transduction; D016212:Transforming Growth Factor beta / Q000378:metabolism*
D018125:Receptors, Transforming Growth Factor beta; D016212:Transforming Growth Factor beta; D017346:Protein Serine-Threonine Kinases; D000077294:Receptor, Transforming Growth Factor-beta Type II